NICE recommends Blincyto (blinatumomab) for treating Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia.Amgen
The National Institute for Health and Care Excellence (NICE) has published its Final Appraisal Determination (FAD) recommending Blincyto (blinatumomab) from Amgen,as an option for treating adults with Philadelphia-chromosome-negative (Ph-) relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL), on the basis of the discount agreed in the patient access scheme. NICE reviewed the data available on the clinical and cost-effectiveness of blinatumomab. Having considered evidence on the nature of the disease and the value placed on the benefits of blinatumomab by people with the condition, those who represent them, and clinical experts, NICE concluded that it is a cost-effective use of NHS resources under the end-of-life criteria.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins